Skip to main content

Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients



Deriving links between imaging and genomic markers is an evolving field. 2-[18F]FDG PET/CT (18F-fluorodeoxyglucose positron emission tomography–computed tomography) is commonly used for cancer imaging, with maximum standardized uptake value (SUVmax) as the main quantitative parameter. Tumor mutational burden (TMB), the quantitative variable obtained using next-generation sequencing on a tissue biopsy sample, is a putative immunotherapy response predictor. We report the relationship between TMB and SUVmax, linking these two important parameters.


In this pilot study, we analyzed 1923 patients with diverse cancers and available TMB values. Overall, 273 patients met our eligibility criteria in that they had no systemic treatment prior to imaging/biopsy, and also had 2-[18F]FDG PET/CT within 6 months prior to the tissue biopsy, to ensure acceptable temporal correlation between imaging and genomic evaluation.


We found a linear correlation between TMB and SUVmax (p < 0.001). In the multivariate analysis, only TMB independently correlated with SUVmax, whereas age, gender, and tumor organ did not.


Our observations link SUVmax in readily available, routinely used, and noninvasive 2-[18F]FDG PET/CT imaging to the TMB, which requires a tissue biopsy and time to process. Since higher TMB has been implicated as a prognostic biomarker for better outcomes after immunotherapy, further investigation will be needed to determine if SUVmax can stratify patient response to immunotherapy.


Creating a link between imaging findings and genomic data in patients with cancer is crucial in the evolving world of genomics. Radiologic markers have shown promise for noninvasive identification of molecular properties [1]. Imaging markers can provide surrogate genomic markers from imaging data for diagnosis, prognosis, and stratification of cancer patients in the emerging field of personalized medicine. Such links between imaging and genomics have been formed in computed tomography (CT) and magnetic resonance imaging (MRI), whereas fewer studies have investigated such relationship in 2-[18F]fluoro-2-deoxy-d-glucose (2-[18F]FDG) positron emission tomography (PET) [2,3,4].

2-[18F]FDG PET/CT is standard of care and plays a pivotal role in cancer diagnosis and staging [5]. The maximum standardized uptake value (SUVmax), a relative measure of FDG uptake, is the most widely used quantitative parameter for the assessment of cancer patients [6, 7]. Traditionally, the SUVmax has been correlated with histopathological findings. As the era of personalized medicine continues to move rapidly toward molecular stratification, there have been studies to associate SUVmax with biologic pathways, although SUVmax is still generally unspecified at a molecular level [4, 8].

Tumor mutational burden (TMB) is defined as the total number of somatic mutations identified per megabase pair (Mbp) of coding area and is quantified using next-generation sequencing (NGS). Tumors with high TMB likely harbor numerous neoantigens created from the mutanome, possibly eliciting an endogenous immune response or enhancing tumor metabolic rate, which may explain the correlation of high TMB and response to checkpoint blockade immunotherapy [9,10,11,12].

Herein, we demonstrate a positive relationship between SUVmax and TMB in patients with cancer. Our finding links SUVmax in readily available, routinely used, and noninvasive 2-[18F]FDG PET/CT imaging to the TMB, which requires a tissue biopsy and time to process. Since higher TMB has been suggested to predict better outcomes after immunotherapy, further prospective study of this association and its implications for cancer immunotherapy are needed.


Patient characteristics

Of 1923 patients in the database, we found 273 patients with metastatic cancer had no systemic treatment prior to imaging/biopsy, and also had 2-[18F]FDG PET/CT within 6 months prior to the tissue biopsy (Table 1). All patients had metastatic (stage IV) disease at the time of blood draw. Because patients with early-stage cancer were not included in the study, the cancer stage was not a variable. Based on the TMB values and prior precedent for cut-off values [13], patients were categorized into three groups: TMB = 0–1 mutations/mb (N = 39 patients, 14%), TMB = 2–11 mutations/mbp (N = 174, 64%), and TMB ≥ 12 mutations/mb (N = 60, 22%); the mean TMB in each group was 0, 5, and 37 mutations/mbp. There was no difference in gender distribution between groups. Patients in the TMB = 2–11 mutations/mb group were slightly younger on average than those in the two other TMB groups (63.9 vs. 68.5 or 68.3 years, p = 0.03). Organ distribution showed statistically significant differences between TMB categories in different cancer types, with higher TMB in melanoma and lung cancer than in breast, gastrointestinal, or “other” cancers (Table 1). The most notable pattern was seen with melanoma, which expectedly had the highest percentage of patients among cancer types in the TMB ≥ 12 mutations/mb category (60% vs. 7–30% in other cancer types) [12, 14].

Table 1 Patient characteristics in three quantiled TMB groups (N = 273 patients)

SUV max correlates with TMB

Median SUVmax was 3.9, 6.8 and 9.2 for the 0–1, 2–11, and ≥ 12 mutations/mb groups (p < 0.0001). Raw diagnostics showed that the TMB is the only variable with statistically significant relationship with SUVmax (p < 0.003) (Table 2). However, due to the highly skewed distributions of both TMB and SUV, shifted-log transformations were used for analysis because statistical model diagnostics indicated that both SUVmax and TMB should be analyzed on the log scale (Table 3). Post hoc analysis showed significant differences between SUVmax in all groups: mean increase in shifted SUVmax values for TMB ≥ 12 mutations/mb category vs. TMB 2–11 category was 38.6% with 95% CI = [11.7%,71.9%] (p < 0.003); mean increase in shifted SUVmax values for TMB ≥ 12 category vs. TMB 0–1 category was 145% with 95% CI = [82.2%, 229.5%] (p < 0.001), and for TMB 2–11 category vs. TMB 0–1 category was 76.8%, with 95% CI = [37.0%,128.2%], (p < 0.001) (Fig. 1). Linear correlation between all shifted-log TMB and shifted-log SUVmax had Pearson correlation coefficient r = 0.34, (p < 0.001) (Fig. 2). Among different cancer types, breast cancer patients showed linear correlation between shifted-log TMB and shifted-log SUVmax with Pearson correlation coefficient r = 0.40, (p = 0.008). This linear correlation coefficient for the lung cancer patients was r = 0.43, (p = 0.001), and for the other cancer patients was r = 0.37 (p < 0.001). For the melanoma and gastrointestinal patients, this relationship was not statistically significant, perhaps due to smaller number of patients in these two groups (N = 15, and 36, respectively).

Table 2 Univariate analysis of relationship of variables to SUVmax in the raw scale
Table 3 Multivariate analysis of relationship of variables to SUVmax in the log scale*
Fig. 1

SUVmax is significantly different between TMB of 0–1, 2–11, and ≥ 12 mutations/mb. The central thick black line indicates the median, and the bottom and top of the rectangle are the 25th (Q1) and 75th (Q3) percentiles. The circles represent outlier SUVmax values, defined as either larger than Q3 + 1.5 × IQR or smaller than Q1 − 1.5 × IQR, where IQR = Q3 − Q1 is the interquartile range. The horizontal “whiskers” represent the largest and smallest non-outlier observations in the data set. All p values are from analysis on log scale

Fig. 2

log(SUVmax + 1) is linearly correlated to log(TMB + 1) (r = 0.34, p < 0.001). The graph is the regression on the shifted-log scale. The circles represent individual data-points

Multivariate analysis of factors affecting SUV max

We found that sex and age had no correlation with SUVmax. Cancer type relationship with SUVmax showed a statistically insignificant trend (with lung cancer having higher SUVmax, albeit not statistically significant) (multivariate p value = 0.08). The only variable that correlated significantly with SUVmax, was TMB; Each unit increase in log(TMB + 1) resulted in a 27.8% increase in (SUVmax + 1) (multivariate p < 0.001) (Table 3).


To our knowledge, this is the first study to investigate the relationship between SUVmax and TMB in patients with diverse cancers. Prior studies have investigated the complex relationship between tumor immune microenvironment and glucose metabolism rate and shown associations between metabolic and immune profiles [15, 16]. 2-[18F]FDG PET imaging has been suggested as a diagnostic tool to estimate tumor immune status [17]. Our hypothesis was that higher mutational load (as reflected by TMB) might correlate with metabolic reconfiguration [18], and immune inflammatory response [12], and that either of these features would be associated with a higher SUVmax [19]. Our study confirmed that higher TMB was the only evaluated variable that independently correlated with higher SUVmax. Of interest, one prior study examined this question, albeit in lung cancer alone [4]. They found no significant relationship between SUVmax and TMB. However, there were some major differences between their study and ours: (1) Moon and colleagues confined their observations to lung cancer, whereas our study included a variety of malignancies; and (2) they did not note the timing of the 2-[18F]FDG PET–CT versus the biopsy [4]. In our study, the biopsy was taken ≤ 6 months before the PET scan. Longer time lapse may cause poor correlation between the SUVmax and TMB parameters. In addition, obtaining PET imaging after the biopsy or after starting the treatment could cause false positive or false negative SUVmax results. Indeed, we studied 1923 diverse cancer patients with TMB values, out of which 273 patients met the criteria of having no prior systemic treatment and having SUVmax performed within 6 months prior to the biopsy. Since having synchronous TMB and SUVmax is ideal, future studies should attempt to obtain biopsies for TMB immediately after PET imaging.

Various cutoffs have been previously established for TMB, including the dichotomization at 12 mutations/mb, to be predictive of immunotherapy response [13]. Upon categorizing patients into three groups based on TMB levels: 0–1, 2–11, and ≥ 12 mutations/mb groups, we found that patients in the higher TMB group have higher SUVmax values and this difference was statistically significant between all three groups with p < 0.0001 (Table 1).

To confirm that the relationship between TMB and SUVmax is independent of confounders, we analyzed the data in multivariate models. The only parameter that showed a significant relationship with SUVmax was TMB (multivariate p < 0.0001), confirming the independent correlation between TMB and SUVmax (Table 3). Further, there was a linear relationship between TMB and SUVmax in the log scale (r = 0.34, p < 0.001) (Fig. 2). Sex, age, and cancer type had no statistically significant association with SUVmax (Table 3).

Several genomic alterations have been related to immunotherapy response, including but not limited to microsatellite instability high (MSI-H) status (which results in high TMB), high TMB itself, PBRM1 mutations, and APOBEC-related mutagenesis [12, 13, 20,21,22]. TMB varies dramatically between tumor types, with skin and lung cancers, having higher median TMBs than most other cancers [23, 24]. Our previous studies indicated that the median TMB for responders vs. non-responders to anti-PD-1/PD-L1 monotherapy was 18.0 vs. 5.0 mutations/Mb, with higher TMB predicting favorable outcomes across diverse tumors [12, 25]. Other studies have found that higher TMB was linked to improved survival following immunotherapy in diverse cancers for the top 20% of TMBs in each histology [26]. Various investigations have used different cutoffs for defining the relationship between TMB and checkpoint blockade response [27] and our own work has suggested a linear correlation between TMB and response [12].

We hypothesize that higher TMB promotes metabolic reconfiguration, causing increased glucose metabolism rate (GMR), and thus higher SUVmax. Carbohydrate metabolism has been previously shown to have correlation with TMB [18]. GMR–TMB correlation could explain our finding of SUVmax–TMB correlation, although the exact mechanism for this finding is not understood [18]. An alternative explanation for the correlation between TMB and SUVmax might be based on an innate immune response to tumors with higher TMB. Indeed, higher TMB correlates with better response to immune checkpoint blockade and it is conceivable that innate immunity might also be triggered in the presence of high mutational load. An immune cell infiltrate would create increased glycolytic activity and an inflammatory response that would manifest as higher SUVmax [28]. We have also previously shown increased SUVmax in tumors with higher number of characterized genomic alterations [29, 30] consistent with this work.

Our study had several important limitations: first it is a retrospective analysis and thus TMB and SUVmax parameters were not fully synchronized; second, although the full cohort included 1923 patients, only 273 patients had PET scans within 6 months before their biopsies for TMB; third, we do not know the mechanism underlying the relationship between TMB and SUVmax; fourth this study was single-center/single-camera, and fifth, a variety of tumor types were included in the analysis, though the latter two may also suggest the homogeneity of PET results and generalizability of results across cancer organs, respectively); and fourth, we did not examine variant genes or molecules associated with SUVmax, which could be key markers of SUVmax [31]. Future studies are needed to expand the number of the patients, and to evaluate such relationship in each individual cancer type. Multicenter study and also same-day PET scans/biopsy for TMB are needed would be needed to validate our findings. Furthermore, exploring the direct relationship between SUVmax and immunotherapy response is future step since we found SUVmax is correlated with TMB and it is known that higher TMB is correlated with immunotherapy response.

Materials and methods

Patient selection

We performed a search and found 1923 patients who had TMB values on biopsy tissue samples obtained by hybrid capture-based NGS (Foundation Medicine) at UC San Diego Moores Cancer Center. Among those, 273 patients had no systemic treatment prior to imaging/biopsy, and also had 2-[18F]FDG PET/CT within 6 months prior to the tissue biopsy, to ensure acceptable temporal correlation between imaging and genomic evaluation.

2-[18F]FDG PET–CT imaging

All patients received PET imaging under standard conditions as needed for their disease assessment. Patients were asked to fast for at least 6 h prior to their scan. Blood glucose levels were measured immediately before the 2-[18F]FDG injection and no patient had a blood glucose level > 8.9 mM. Patients were injected with 370–740 MBq 2-[18F]FDG, intravenously, within 5–10 s. Following an uptake period of approximately one hour in a quiet room at rest, multi-station 3-dimensional (3D) whole-body PET acquisition with CT (for attenuation correction) was performed for approximately 60 min, using the same GE Discovery VCT scanner (GE, Waukesha, WI) for all the patients. The scanner was in compliance with American College of Radiology guidelines. Whole-body CT covered the region from the head to the mid-thigh. PET images were acquired, after the CT scan, at a rate of 2 min/bed position, in the 3 dimensional (3D) acquisition mode. CT images were then reconstructed onto a 512 × 512 matrix. PET images were reconstructed using a standard whole-body 3D iterative reconstruction: 2 iterations; 28 subsets onto a 128 × 128 matrix with attenuation correction, decay correction, and scatter correction. The photon energy window was 425–650 keV. Slice thickness was 3.27 mm and reconstruction diameter was 70 cm. Pixel size was 5.47 mm × 5.47 mm with spatial resolution of 5 mm. 2-[18F]FDG PET/ CT images were generated for review on a workstation.

Image analysis

All PET images were interpreted on the institution’s pictures archiving and communication system (PACS), (AGFA Impax 6.3, Mortsel Belgium) by a board-certified academic nuclear medicine physician/radiologist and verified by a second nuclear medicine physician/radiologist. Focal activities of the lesions were manually identified on the PET images. SUVs of the lesions were obtained by manually placing a circular region of interest (ROI) at the site of the maximum 2-[18F]FDG uptake in the PET images and the maximal activity (SUVmax) was recorded. The SUV was calculated as decay-corrected activity of tissue volume (kBq /mL)/injected 2-[18F]FDG activity per body mass (kBq/g). In most of the cases, the biopsied lesion was selected for analysis; however, if the biopsied lesion was smaller than 1 cm, the most FDG-avid lesion, larger than 1 cm, was selected, to avoid partial volume effect. Therefore, all the lesions that underwent SUVmax analysis, were > 1 cm diameter. For patients showing no focal 2-[18F]FDG uptake on PET, a rounded SUVmax of 0 was recorded. It should be noted that those patients with only background uptake have no elevated glucose uptake; the exact SUVmax number may vary in these different patients due to technique and background, so they were all rounded to 0, for a more accurate representation.

Evaluation of TMB

Formalin-fixed, paraffin-embedded tumors were submitted for NGS to Foundation Medicine (clinical laboratory improvement amendments (CLIA)-certified lab). The Foundation One assay was used (hybrid-capture-based NGS; 182, 236, or 315 genes, depending on the time period). The methods have been previously described [32]. Average sequencing depth of coverage was > 250 × , with > 100 × at > 99% of exons. For TMB, the number of somatic mutations detected by interrogating 1.2 mb of the genome were quantified and that value extrapolated to the whole exome using a validated algorithm. Alterations likely or known to be oncogenic drivers as well as germline polymorphisms were excluded. TMB was measured in mutations per megabase pair (Mbp). TMB levels were divided into three groups based off the Foundation Medicine official reports: 0–1, 2–11, and ≥ 12 mutations/mb.

Statistical analysis

Statistical analysis was done in R, version 4.0.2. Statistical model diagnostics indicated that both SUVmax and TMB should be analyzed on the log scale. Since there were multiple rounded zero values in both SUVmax and TMB values, they were transformed with a shifted-log by adding 1 before taking the natural logarithm. The TMB data were also grouped into three TMB quantiles (0–1, 2–11, and ≥ 12 mutations/Mb) for analysis as a categorical variable. The categorized TMB data were analyzed for association with the shifted-log SUVmax values by ANOVA, with sex by Fisher’s Exact test, and with cancer type by a chi-squared test. The shifted-log SUVmax was regressed on the shifted-log TMB and on age in years and was also used as the response variable in ANOVAs with sex and cancer type. The variables with p < 0.1 in these four analyses were then used in a general linear model with SUVmax as the response variable. Differences between groups were considered to be significant at a p value ≤ 0.05 and confidence intervals (CI) were done at confidence level 95%. The geometric mean was used for some analysis (geometric mean of N numbers is the nth root of the product of the numbers). Data are reported as mean ± standard deviation (SD).


We found a linear positive correlation between TMB and SUVmax in diverse cancers. Of the features evaluated, multivariate analysis showed TMB to be the only factor independently associated with SUVmax. Future prospective studies with PET scans and biopsy for TMB done on the same day are needed to validate the findings in this area. Furthermore, it will be important to determine if tumors with higher SUVmax respond better to immunotherapy, as might be expected, since higher TMB is correlated with immunotherapy response [12].

Availability of data and materials

Not applicable.


2-[18F]FDG PET/CT:

2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography–computed tomography

SUVmax :

Standardized uptake value


Tumor mutational burden


Magnetic resonance imaging


Megabase pair


Next-generation sequencing


Pictures archiving and communication system


Region of interest


Glucose metabolism rate


  1. 1.

    Jansen RW, van Amstel P, Martens RM, Kooi IE, Wesseling P, de Langen AJ, et al. Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis. Oncotarget. 2018;9:20134–55.

    Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Segal E, Sirlin CB, Ooi C, Adler AS, Gollub J, Chen X, et al. Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol. 2007;25:675–80.

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Diehn M, Nardini C, Wang DS, McGovern S, Jayaraman M, Liang Y, et al. Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci U S A. 2008;105:5213–8.

    Article  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Moon SH, Kim J, Joung JG, Cha H, Park WY, Ahn JS, et al. Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer. Eur J Nucl Med Mol Imaging. 2019;46:446–54.

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49:480–508.

    Article  PubMed  Google Scholar 

  6. 6.

    Lodge MA. Repeatability of SUV in oncologic. J Nucl Med. 2017;58:523–32.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  7. 7.

    Thie JA. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med. 2004;45:1431–4.

    PubMed  Google Scholar 

  8. 8.

    Ahn KS, Kang KJ, Kim YH, Kim TS, Song BI, Kim HW, et al. Genetic features associated with 18F-FDG uptake in intrahepatic cholangiocarcinoma. Ann Surg Treat Res. 2019;96:153–61.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30:44–56.

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124–212.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371:2189–99.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  12. 12.

    Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16:2598–608.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Goodman AM, Kato S, Chattopadhyay R, Okamura R, Saunders IM, Montesion M, et al. Phenotypic and genomic determinants of immunotherapy response associated with squamousness. Cancer Immunol Res. 2019.

    Article  PubMed  PubMed Central  Google Scholar 

  14. 14.

    Maleki VS. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J Immunother Cancer. 2018;6:157.

    Article  Google Scholar 

  15. 15.

    Na KJ, Choi H. Tumor metabolic features identified by 18F-FDG PET correlate with gene networks of immune cell microenvironment in head and neck cancer. J Nucl Med. 2018;59:31–7.

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Park C, Na KJ, Choi H, Ock CY, Ha S, Kim M, et al. Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma. Theranostics. 2020;10:10838–48.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Togo M, Yokobori T, Shimizu K, Handa T, Kaira K, Sano T, et al. Diagnostic value of 18 F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8 + tumour-infiltrating lymphocytes in oral squamous cell carcinoma. Br J Cancer. 2020;122:1686–94.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  18. 18.

    Choi H, Na KJ. Pan-cancer analysis of tumor metabolic landscape associated with genomic alterations. Mol Cancer. 2018;17:150.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  19. 19.

    Zikou A, Sioka C, Alexiou GA, Fotopoulos A, Voulgaris S, Argyropoulou MI. Radiation necrosis, pseudoprogression, pseudoresponse, and tumor recurrence: imaging challenges for the evaluation of treated gliomas. Contrast Media Mol Imaging. 2018;2018:6828396.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  20. 20.

    Mouw KW, Goldberg MS, Konstantinopoulos PA, D’Andrea AD. DNA damage and repair biomarkers of immunotherapy response. Cancer Discov. 2017;7:675–93.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  21. 21.

    Otto G. Kidney cancer: PBRM1 loss promotes tumour response to immunotherapy. Nat Rev Clin Oncol. 2018;15:134–5.

    Article  PubMed  Google Scholar 

  22. 22.

    Boichard A, Pham TV, Yeerna H, Goodman A, Tamayo P, Lippman S, et al. APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy. Oncoimmunology. 2019;8:1550341.

    Article  PubMed  Google Scholar 

  23. 23.

    Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9:34.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  24. 24.

    Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–21.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  25. 25.

    Goodman A, Patel SP, Kurzrock R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol. 2017;14:203–20.

    CAS  Article  PubMed  Google Scholar 

  26. 26.

    Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51:202–6.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  27. 27.

    Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378:2093–104.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  28. 28.

    Aide N, Hicks RJ, Le Tourneau C, Lheureux S, Fanti S, Lopci E. FDG PET/CT for assessing tumour response to immunotherapy : Report on the EANM symposium on immune modulation and recent review of the literature. Eur J Nucl Med Mol Imaging. 2019;46:238–50.

    Article  PubMed  Google Scholar 

  29. 29.

    Chang GH, Kurzrock R, Tran L, Schwaederle M, Hoh CK. mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT). Oncotarget. 2018;9:14306–10.

    Article  PubMed  PubMed Central  Google Scholar 

  30. 30.

    Haghighat Jahromi A, Chang C, Hoh CK, Kurzrock R. Standardized uptake value (SUVmax) in 18F-FDG PET/CT is correlated with the total number of main oncogenic anomalies in cancer patients. Cancer Biol Ther. 2020.

    Article  PubMed  Google Scholar 

  31. 31.

    Kim SK, Ahn SG, Mun JY, Jeong MS, Bae SJ, Lee JS, et al. Genomic signature of the standardized uptake value in 18F-Fluorodeoxyglucose positron emission tomography in breast cancer. Cancers (Basel). 2020.

    Article  PubMed Central  Google Scholar 

  32. 32.

    Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31:1023–31.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references


Not applicable.


Amin Haghighat Jahromi is supported by NIH T32-4T32EB005970 grant. This work was also supported in part by the Joan and Irwin Jacobs Fund philanthropic fund, and by National Cancer Institute at the National Institutes of Health Grant P30 CA023100.

Author information




AHJ contributed to conceptualization, data curation, writing—original draft, and editing. DAB contributed to formal analysis. MZ, AMG, GF, and MN curated the data. CKH and RK contributed to conceptualization and writing—review and editing. All authors contributed to significant intellectual input and review and approval of final manuscript.

Corresponding author

Correspondence to Amin Haghighat Jahromi.

Ethics declarations

Ethics approval and consent to participate

This study was performed and consent obtained in accordance with the guidelines of the UCSD Internal Review Board (PREDICT [Profile Related Evidence Determining Individualized Cancer Therapy], protocol; NCT02478931).

Consent for publication

The manuscript has been seen and approved by all authors. We certify that the manuscript is not under consideration for publication and has not been published elsewhere in any public medium including electronic journals and computer databases.

Competing interests

Razelle Kurzrock receives research funding from Genentech, Incyte, Merck Serono, Pfizer, Sequenom, Foundation Medicine, Grifols, Konica Minolta, Omniseq, and Guardant, as well as consultant fees from Loxo, X Biotech, NeoMed, and Actuate Therapeutics, speaker fees from Roche, and an equity interest in IDbyDNA and Curematch Inc. Aaron Goodman receives speaking fees from Seattle Genetics and consulting fees from Jazz Pharmaceuticals, Daiichi Sankyo, Kyowa Kirin, and Navican. Donald Barkauskas has a close relation who is employed by Genentech.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Haghighat Jahromi, A., Barkauskas, D.A., Zabel, M. et al. Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients. EJNMMI Res 10, 150 (2020).

Download citation


  • Tumor mutational burden
  • SUVmax
  • Cancer
  • Immunotherapy